Page last updated: 2024-12-11

n,n'-desoxycarbadox

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N,N'-desoxycarbadox: metabolite of carbadox [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9568819
SCHEMBL ID10596267
MeSH IDM0128285

Synonyms (20)

Synonym
(2-quinoxalinylmethylene)hydrazinecarboxylic acid methyl ester
n,n'-desoxycarbadox
carbadox, deoxy-
hydrazinecarboxylic acid, (2-quinoxalinylmethylene)-, methyl ester
brn 0799004
desoxycarbadox
xu4n6mkp8r ,
unii-xu4n6mkp8r
55456-55-8
5-24-03-00423 (beilstein handbook reference)
n,n'-deoxycarbadox
SCHEMBL10596267
methyl 3-(2-quinoxalinylmethylene) carbazate
desoxycarbadox, vetranal(tm), analytical standard
1448350-02-4
methyl n-[(e)-quinoxalin-2-ylmethylideneamino]carbamate
CS-0129350
HY-136428
hydrazinecarboxylic acid, 2-(2-quinoxalinylmethylene)-, methyl ester
AKOS040758193
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (50.00)18.7374
1990's1 (50.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.66 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]